Bath Savings Trust Co Reduces Holdings in Danaher Corporation $DHR

Bath Savings Trust Co lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 8.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 59,099 shares of the conglomerate’s stock after selling 5,777 shares during the quarter. Danaher makes up 1.2% of Bath Savings Trust Co’s portfolio, making the stock its 26th largest holding. Bath Savings Trust Co’s holdings in Danaher were worth $11,717,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Ceredex Value Advisors LLC boosted its stake in Danaher by 1.6% in the 2nd quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after purchasing an additional 3,862 shares during the period. Chicago Capital LLC increased its holdings in shares of Danaher by 11.6% in the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after buying an additional 1,391 shares during the last quarter. Weitz Investment Management Inc. raised its position in Danaher by 6.1% during the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock valued at $104,094,000 after purchasing an additional 30,300 shares during the period. UniSuper Management Pty Ltd raised its holdings in Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after buying an additional 2,667 shares during the period. Finally, Nvwm LLC lifted its holdings in shares of Danaher by 20.4% in the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after acquiring an additional 1,204 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DHR has been the subject of a number of recent analyst reports. TD Cowen boosted their price objective on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Rothschild Redb cut shares of Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price target (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Twenty-one equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $248.25.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 3,298 shares of Danaher stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director owned 20,762 shares in the company, valued at $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,248 shares of company stock valued at $6,609,663 over the last quarter. 11.10% of the stock is owned by corporate insiders.

Danaher Price Performance

Shares of DHR opened at $224.43 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The company has a 50 day moving average price of $219.93 and a 200-day moving average price of $206.66. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The stock has a market capitalization of $158.53 billion, a PE ratio of 46.28, a PEG ratio of 4.32 and a beta of 0.89.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. Danaher’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.71 earnings per share. Equities analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s dividend payout ratio is 26.39%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.